Pharmaceutical manufacturers have targeted and attacked the 340B Drug Pricing Program for the past few months. Their actions caused the National Rural Health Association to send a letter to U.S. Department of Health and Human Services (HHS) Secretary Alex Azar urging him to instruct the Health Resources and Services Administration (HRSA) to exert all regulatory authority to rein in these pharmaceutical manufacturers and ensure the longevity and integrity of this critical lifeline. In response, HRSA told 340B Report they are investigating whether manufacturer policies to restrict 340B pricing at contract pharmacies violates statute. Members of Congress returned to Washington, D.C. with a renewed focus on protecting the 340B program. Several letters, including one authored by Representatives McKinley (R-WV) and DeGette (D-CO) have circulated among Capitol Hill offices for Members to sign-on.
